Liquidia (LQDA) Competitors

Jazz Pharmaceuticals has a net margin of 4.37% compared to Liquidia's net margin of -15.15%. Liquidia's return on equity of 264.65% beat Jazz Pharmaceuticals' return on equity.

Jazz Pharmaceuticals has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market. Comparatively, Liquidia has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market.

Jazz Pharmaceuticals currently has a consensus target price of $294.25, suggesting a potential upside of 21.82%. Liquidia has a consensus target price of $75.23, suggesting a potential upside of 31.04%. Given Liquidia's higher possible upside, analysts clearly believe Liquidia is more favorable than Jazz Pharmaceuticals.

In the previous week, Liquidia had 12 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 31 mentions for Liquidia and 19 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 0.87 beat Liquidia's score of 0.63 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.

89.1% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 64.5% of Liquidia shares are held by institutional investors. 4.1% of Jazz Pharmaceuticals shares are held by company insiders. Comparatively, 25.6% of Liquidia shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Liquidia has lower revenue, but higher earnings than Jazz Pharmaceuticals. Liquidia is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Dr. Reddy's Laboratories has a net margin of 8.56% compared to Liquidia's net margin of -15.15%. Liquidia's return on equity of 264.65% beat Dr. Reddy's Laboratories' return on equity.

In the previous week, Liquidia had 22 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 31 mentions for Liquidia and 9 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 1.09 beat Liquidia's score of 0.63 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media.

Dr. Reddy's Laboratories has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Comparatively, Liquidia has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market.

Dr. Reddy's Laboratories has higher revenue and earnings than Liquidia. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Dr. Reddy's Laboratories currently has a consensus price target of $492.90, indicating a potential upside of 3,238.30%. Liquidia has a consensus price target of $75.23, indicating a potential upside of 31.04%. Given Dr. Reddy's Laboratories' higher probable upside, analysts clearly believe Dr. Reddy's Laboratories is more favorable than Liquidia.

3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 64.5% of Liquidia shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Comparatively, 25.6% of Liquidia shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Liquidia has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

64.5% of Liquidia shares are owned by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are owned by institutional investors. 25.6% of Liquidia shares are owned by insiders. Comparatively, 1.1% of Elanco Animal Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Liquidia has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.73, indicating that its share price is 73% more volatile than the broader market.

Elanco Animal Health has a net margin of -2.86% compared to Liquidia's net margin of -15.15%. Liquidia's return on equity of 264.65% beat Elanco Animal Health's return on equity.

In the previous week, Liquidia had 14 more articles in the media than Elanco Animal Health. MarketBeat recorded 31 mentions for Liquidia and 17 mentions for Elanco Animal Health. Liquidia's average media sentiment score of 0.63 beat Elanco Animal Health's score of 0.48 indicating that Liquidia is being referred to more favorably in the media.

Liquidia presently has a consensus target price of $75.23, suggesting a potential upside of 31.04%. Elanco Animal Health has a consensus target price of $29.75, suggesting a potential upside of 11.01%. Given Liquidia's higher possible upside, analysts clearly believe Liquidia is more favorable than Elanco Animal Health.

93.6% of Corcept Therapeutics shares are held by institutional investors. Comparatively, 64.5% of Liquidia shares are held by institutional investors. 20.7% of Corcept Therapeutics shares are held by company insiders. Comparatively, 25.6% of Liquidia shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Corcept Therapeutics has higher revenue and earnings than Liquidia. Liquidia is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Corcept Therapeutics has a net margin of 16.53% compared to Liquidia's net margin of -15.15%. Liquidia's return on equity of 264.65% beat Corcept Therapeutics' return on equity.

In the previous week, Liquidia had 19 more articles in the media than Corcept Therapeutics. MarketBeat recorded 31 mentions for Liquidia and 12 mentions for Corcept Therapeutics. Liquidia's average media sentiment score of 0.63 beat Corcept Therapeutics' score of 0.24 indicating that Liquidia is being referred to more favorably in the news media.

Corcept Therapeutics presently has a consensus target price of $139.50, suggesting a potential upside of 91.25%. Liquidia has a consensus target price of $75.23, suggesting a potential upside of 31.04%. Given Corcept Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Corcept Therapeutics is more favorable than Liquidia.

Corcept Therapeutics has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market. Comparatively, Liquidia has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market.